Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Previous Page

Next Page

Page Background

Survival linked to sequence?

PROFILE 1014

3y-OS: 78%

ALECTINIB phI/II

Salomon – JCO 2018 * Tamura – JCO 2017

3y-OS: 60%82

Crizotinib

à

ALK TKI

CT

à

any ALK TKI

CT

à

other than ALK TKI

Crizotinib

à

other than ALK TKI

300 mg BID